Investors focused on the Medical space have likely heard of Bio-Rad Laboratories (BIO), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of BIO and the rest of the Medical group's stocks.
Bio-Rad Laboratories is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BIO is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BIO's full-year earnings has moved 8.12% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that BIO has returned about 25.48% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.84% on average. This means that Bio-Rad Laboratories is outperforming the sector as a whole this year.
Looking more specifically, BIO belongs to the Medical - Products industry, a group that includes 70 individual stocks and currently sits at #100 in the Zacks Industry Rank. On average, this group has gained an average of 11.30% so far this year, meaning that BIO is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BIO. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
To read this article on Zacks.com click here.